Yaris, N. Et Al. 2002. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH , vol.21, no.2 , 165-170.

Yaris, N., Ceviz, N., Coskun, T., Akyuz, C., & Buyukpamukcu, M., (2002). Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH , vol.21, no.2, 165-170.

Yaris, N Et Al. "Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity," JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH , vol.21, no.2, 165-170, 2002

Yaris, N Et Al. "Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity." JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH , vol.21, no.2, pp.165-170, 2002

Yaris, N. Et Al. (2002) . "Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity." JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH , vol.21, no.2, pp.165-170.

@article{article, author={N Yaris Et Al. }, title={Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity}, journal={JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH}, year=2002, pages={165-170} }